Genadi Iosava
Tbilisi, TB, Georgia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.
Journal: Research and practice in thrombosis and haemostasis
Published: June 22, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
Journal: Journal of blood medicine
Published: January 06, 2021
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: November 04, 2019
Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).
Journal: Journal of blood medicine
Published: October 31, 2019
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Journal: The New England journal of medicine
Published: December 13, 2017
Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
Journal: Journal of thrombosis and haemostasis : JTH
Published: June 03, 2016
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Journal: The New England journal of medicine
Published: May 11, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026